<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01999192</url>
  </required_header>
  <id_info>
    <org_study_id>986_TREAT 2b</org_study_id>
    <secondary_id>2013-000114-38</secondary_id>
    <secondary_id>BT986</secondary_id>
    <nct_id>NCT01999192</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis</brief_title>
  <acronym>986</acronym>
  <official_title>A 24-week Phase IIb, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Tregalizumab (BT061) in Combination With Methotrexate in the Treatment of Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Alone, Followed by a 24-week Extension Phase: T Cell REgulating Arthritis Trial 2b (TREAT 2b)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotest</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Biotest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of three different
      Tregalizumab doses in combination with Methotrexate (MTX) in subjects who have active
      rheumatoid arthritis and an inadequate response to MTX alone.

      The overall study duration is 24 weeks followed by a 24 week extension phase.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The planned clinical study 986 (TREAT 2b) is a 24-week study in patients with Active
      rheumatoid arthritis (RA) who have had an inadequate response to Methotrexate (MTX) alone.
      The main phase of this study is followed by a 24-week extension phase for subjects meeting
      the respective entry criteria. Patients will be randomized to one of three different Active
      treatment groups or Placebo. The primary efficacy variable is the proportion of subjects with
      an ACR20 response after 12 weeks of double blinded treatment with the study medication based
      on observed cases in the FAS.

      At Week 12, all subjects who had a minimum improvement of at least 20% (from baseline) in
      their tender joint count (TJC) and swollen joint count (SJC) continued on the same treatment.
      Subjects who had not demonstrated an improvement of at least 20% of TJC and SJC were assessed
      as non-responders. Non-responders who received placebo were randomized to an active treatment
      dose in a blinded manner. Non-responders who received active treatment were rolled up to the
      next highest dose in a blinded manner, apart from those already on the highest dose. These
      subjects remained on the highest dose.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of efficacy
  </why_stopped>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Proportion of Subjects Who Achieve an ACR20 at Week 12 Following Treatment With Tregalizumab + MTX Compared With Subjects Treated on Placebo + MTX</measure>
    <time_frame>Week 12</time_frame>
    <description>The primary efficacy variable was the proportion of subjects with an ACR20 response after 12 weeks of double-blind treatment with the study medication.
The analysis of the primary endpoint was performed using observed cases (OC) on the FAS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportions of Subjects With an ACR 20 Response.</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of Subjects With an ACR 50 &amp; 70 Response.</measure>
    <time_frame>Week 12 &amp; Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of Subjects With an Disease Activity Score DAS28 &lt;2.6</measure>
    <time_frame>Week 12 &amp; Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of Subjects With Low Disease Activity DAS28 ≤3.2</measure>
    <time_frame>Week 12 &amp; Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR Score</measure>
    <time_frame>up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Simple Disease Activity Index [SDAI] ≤11</measure>
    <time_frame>week 12 &amp; 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Disease Activity Index [CDAI] ≤10</measure>
    <time_frame>week 12 &amp; 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DAS28</measure>
    <time_frame>up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EULAR Response</measure>
    <time_frame>up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR Score Individual Components</measure>
    <time_frame>up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DAS28 Score Individual Components</measure>
    <time_frame>up to 48 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>AUC, Cmax, Tmax at baseline, and at Week (W) 2/Visit (V) 4, W4/V5, W8/V7, W12/V8, W24/V10, W3/V122, W48 (end of Treatment [EoT]/ early termination ET), and at follow-up (post EoT/post ET).</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of Safety, Patient Reported Outcomes &amp; Blood Tests.</measure>
    <time_frame>up to 48 weeks</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">321</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Dose Level 1 Tregalizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25mg Tregalizumab s.c. weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 2 Tregalizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100mg Tregalizumab s.c. weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 3 Tregalizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200mg Tregalizumab s.c. weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo s.c. weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tregalizumab</intervention_name>
    <description>humanized anti-CD4 mAb</description>
    <arm_group_label>Dose Level 1 Tregalizumab</arm_group_label>
    <arm_group_label>Dose Level 2 Tregalizumab</arm_group_label>
    <arm_group_label>Dose Level 3 Tregalizumab</arm_group_label>
    <other_name>BT061</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>identical end formulation buffer</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject demonstrates active RA according to the 1987 American College of Rheumatology
             (ACR) or 2010 ACR/European League Against Rheumatism (EULAR) classification criteria
             for RA with functional class I-III for ≥6 months.

          2. Subject receives oral or parenteral MTX treatment for ≥12 weeks (overall), with an
             unchanged mode of application and stable MTX dose of ≥15 mg per week (or ≥12.5 mg per
             week in case of MTX intolerance), but no more than the highest locally approved dose
             for RA, for ≥8 weeks prior to baseline. The dose of MTX is expected to remain stable
             throughout the study and may be adjusted only for safety reasons. If applicable, the
             dose of folic acid must be unchanged for ≥8 weeks prior to baseline.

          3. Subject meets the following two criteria at both screening and baseline: − At least 6
             swollen joints at 28-joint assessment. − At least 6 tender joints at 28-joint
             assessment.

          4. Subject has an erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) above
             the upper limit of normal (ULN) at screening. These tests may be repeated once during
             the screening period at the discretion of the investigator.

          5. Subject is ≥18 and ≤75 years of age.

          6. Subject has a body mass index ≥18 and ≤35 kg/m².

          7. Subject receives treatment with corticosteroids ≤10 mg prednisone equivalent, stable
             for at least 4 weeks prior to baseline and during the study, if applicable.

          8. Subject receives treatment with non-steroidal anti-inflammatory drugs (NSAIDs), stable
             for at least 2 weeks prior to baseline and during the study, if applicable.

          9. Female subjects of childbearing potential: has both a negative serum pregnancy test at
             screening and a negative urine pregnancy test at baseline.

         10. Subject is judged to be in good general health as determined by the investigator based
             upon the results of medical history, laboratory profile, physical examination, chest
             X-ray (within 3 months before screening date is acceptable), and 12−lead
             electrocardiogram (ECG).

         11. Subject has a cluster of differentiation 4 (CD4) cell count of &gt; 400/µl at screening.

        Exclusion Criteria:

          1. Subject has previous exposure to any systemic biologic therapy (e.g., etanercept,
             adalimumab, rituximab, abatacept, tocilizumab), to Janus kinase (JAK) or spleen
             tyrosine kinase (SYK) inhibitors, or to Tregalizumab. Previous treatment with an
             anti-TNF agent is allowed only, if all of the following criteria apply: − treatment
             was stopped for reasons other than lack of efficacy or adverse events (AEs) −
             treatment was stopped at least 12 weeks or five half-lives of the compound prior to
             baseline (whichever is longer), and − the treatment period did not exceed 6 weeks.

          2. Subject received treatment with conventional disease-modifying anti-rheumatic drugs
             (DMARDs) apart from MTX in the 12 weeks prior to baseline, and for DMARD leflunomide
             in the 24 weeks prior to baseline (except where specific leflunomide wash-out
             procedures were completed, following applicable guidelines).

          3. Subject has been treated with intra-articular or parenteral administration of
             corticosteroids in the 4 weeks prior to baseline. Inhaled corticosteroids for stable
             medical conditions are allowed.

          4. Subject has undergone joint surgery in the 12 weeks prior to baseline (at joints to be
             assessed within the study) or has undergone major surgery (e.g., abdominal surgery) in
             the 8 weeks prior to baseline.

          5. Subject has a history of acute inflammatory joint disease of an origin other than RA
             or subject has any other rheumatic disease other than RA (e.g., mixed connective
             tissue disease, seronegative spondylarthropathy, psoriatic arthritis, Reiter's
             syndrome, fibromyalgia, systemic lupus erythematosus or any arthritis with onset prior
             to age 17 years). However, subjects may have secondary Sjögren's syndrome.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald van Vollenhoven, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Universitetssjukhuset, Solna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Study Site 07</name>
      <address>
        <city>Paradise Valley</city>
        <state>Arizona</state>
        <zip>85253</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 01</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 03</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 02</name>
      <address>
        <city>Clifton</city>
        <state>New Jersey</state>
        <zip>07012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 04</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 05</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 09</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 10</name>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <zip>77450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 01</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 06</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 02</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 04</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 07</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 05</name>
      <address>
        <city>Stara Zagora</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 03</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 02</name>
      <address>
        <city>Rimouski</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 01</name>
      <address>
        <city>St-Jérôme</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 03</name>
      <address>
        <city>Bruntal</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 05</name>
      <address>
        <city>Ostrava</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 01</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 04</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 08</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 09</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 02</name>
      <address>
        <city>Uherske Hradiste</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 07</name>
      <address>
        <city>Uherske Hradiste</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 06</name>
      <address>
        <city>Zlin</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 01</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 03</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 04</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 06</name>
      <address>
        <city>Muenchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 02</name>
      <address>
        <city>Ratingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 01</name>
      <address>
        <city>Zerbst</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 03</name>
      <address>
        <city>Balatonfüred</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 02</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 04</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 05</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 06</name>
      <address>
        <city>Gyula</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 01</name>
      <address>
        <city>Veszprem</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 01</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 02</name>
      <address>
        <city>Vilnus</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 05</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 08</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 06</name>
      <address>
        <city>Leon</city>
        <state>Guanajuato</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 02</name>
      <address>
        <city>Chihuahua</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 03</name>
      <address>
        <city>Distrito Federal</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 08</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 05</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 10</name>
      <address>
        <city>Elblag</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 04</name>
      <address>
        <city>Gdynia</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 02</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 03</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 06</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 09</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 01</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 07</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 08</name>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 11</name>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 04</name>
      <address>
        <city>Kursk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 03</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 07</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 10</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 05</name>
      <address>
        <city>Omsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 09</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 06</name>
      <address>
        <city>Smolensk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 01</name>
      <address>
        <city>Tomsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 02</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 01</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 02</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 04</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 03</name>
      <address>
        <city>Niska Banja</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 03</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 04</name>
      <address>
        <city>Kosice - Saca</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 05</name>
      <address>
        <city>Lucenec</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 02</name>
      <address>
        <city>Povazska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 01</name>
      <address>
        <city>Rimavska Sobota</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 08</name>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 01</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 02</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 03</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 04</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 05</name>
      <address>
        <city>Vinnytsia</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 06</name>
      <address>
        <city>Vinnytsia</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 07</name>
      <address>
        <city>Vinnytsia</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 09</name>
      <address>
        <city>Zaporizhzhia</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Estonia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Sweden</country>
  </removed_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2013</study_first_submitted>
  <study_first_submitted_qc>December 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2013</study_first_posted>
  <results_first_submitted>March 16, 2017</results_first_submitted>
  <results_first_submitted_qc>July 25, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 24, 2017</results_first_posted>
  <last_update_submitted>July 25, 2017</last_update_submitted>
  <last_update_submitted_qc>July 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>inadequate response to MTX</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>rheumatoid Arthritis</keyword>
  <keyword>Phase 2b</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dose Level 1 Tregalizumab</title>
          <description>25mg Tregalizumab s.c. weekly</description>
        </group>
        <group group_id="P2">
          <title>Dose Level 2 Tregalizumab</title>
          <description>100mg Tregalizumab s.c. weekly</description>
        </group>
        <group group_id="P3">
          <title>Dose Level 3 Tregalizumab</title>
          <description>200mg Tregalizumab s.c. weekly</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo s.c. weekly</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Main Phase I</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="80"/>
                <participants group_id="P3" count="78"/>
                <participants group_id="P4" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="70"/>
                <participants group_id="P3" count="70"/>
                <participants group_id="P4" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Main Phase II</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="64">Non-responders were switched to higher dose Level after Main Phase 1, started = completed -switched.</participants>
                <participants group_id="P2" count="75">started Patient = completed patients + switched patients (non-responder) from other arms.</participants>
                <participants group_id="P3" count="98">started Patient = completed patients + switched patients (non-responder) from other arms.</participants>
                <participants group_id="P4" count="44">non-responders were switched to higher dose Level after Main Phase 1, started = completed -switched</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="76"/>
                <participants group_id="P4" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Extension Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54">Some patients terminated or were switched to higher dose Level after Main Phase 2.</participants>
                <participants group_id="P2" count="56">Some patients terminated or were switched to higher dose Level after Main Phase 2.</participants>
                <participants group_id="P3" count="68">Some patients terminated after Main Phase 2.</participants>
                <participants group_id="P4" count="0">No Placebo arm for Extension Phase, all patients terminated or were switched to tregalizumab Groups.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="44"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>8 subjects of 321 who had no post-baseline assessment were excluded from the Full Analysis Set (FAS), (one subject [1.3%] in the placebo group, three subjects [3.6%] in Dose Level 1 Tregalizumab group, two subjects [2.5%] in Dose Level 2 Tregalizumab group, and two subjects [2.6%] in Dose Level 3 Tregalizumab group).</population>
      <group_list>
        <group group_id="B1">
          <title>Dose Level 1 Tregalizumab</title>
          <description>25mg Tregalizumab s.c. weekly</description>
        </group>
        <group group_id="B2">
          <title>Dose Level 2 Tregalizumab</title>
          <description>100mg Tregalizumab s.c. weekly</description>
        </group>
        <group group_id="B3">
          <title>Dose Level 3 Tregalizumab</title>
          <description>200mg Tregalizumab s.c. weekly</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo s.c. weekly</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="80"/>
            <count group_id="B2" value="78"/>
            <count group_id="B3" value="76"/>
            <count group_id="B4" value="79"/>
            <count group_id="B5" value="313"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0-&lt;40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40-&lt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="57"/>
                    <measurement group_id="B5" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="66"/>
                    <measurement group_id="B5" value="263"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Proportion of Subjects Who Achieve an ACR20 at Week 12 Following Treatment With Tregalizumab + MTX Compared With Subjects Treated on Placebo + MTX</title>
        <description>The primary efficacy variable was the proportion of subjects with an ACR20 response after 12 weeks of double-blind treatment with the study medication.
The analysis of the primary endpoint was performed using observed cases (OC) on the FAS.</description>
        <time_frame>Week 12</time_frame>
        <population>The analysis of the primary endpoint was performed using observed cases (OC) on the FAS.
Full analysis set (FAS): All subjects entered into the study who received at least one dose of study medication and have at least one post-baseline assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 1 Tregalizumab</title>
            <description>25mg Tregalizumab s.c. weekly</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 2 Tregalizumab</title>
            <description>100mg Tregalizumab s.c. weekly</description>
          </group>
          <group group_id="O3">
            <title>Dose Level 3 Tregalizumab</title>
            <description>200mg Tregalizumab s.c. weekly</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo s.c. weekly</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Subjects Who Achieve an ACR20 at Week 12 Following Treatment With Tregalizumab + MTX Compared With Subjects Treated on Placebo + MTX</title>
          <description>The primary efficacy variable was the proportion of subjects with an ACR20 response after 12 weeks of double-blind treatment with the study medication.
The analysis of the primary endpoint was performed using observed cases (OC) on the FAS.</description>
          <population>The analysis of the primary endpoint was performed using observed cases (OC) on the FAS.
Full analysis set (FAS): All subjects entered into the study who received at least one dose of study medication and have at least one post-baseline assessment.</population>
          <units>percentage of Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.3"/>
                    <measurement group_id="O2" value="47.0"/>
                    <measurement group_id="O3" value="44.3"/>
                    <measurement group_id="O4" value="35.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportions of Subjects With an ACR 20 Response.</title>
        <time_frame>Week 24</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportions of Subjects With an ACR 50 &amp; 70 Response.</title>
        <time_frame>Week 12 &amp; Week 24</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportions of Subjects With an Disease Activity Score DAS28 &lt;2.6</title>
        <time_frame>Week 12 &amp; Week 24</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportions of Subjects With Low Disease Activity DAS28 ≤3.2</title>
        <time_frame>Week 12 &amp; Week 24</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACR Score</title>
        <time_frame>up to 48 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Simple Disease Activity Index [SDAI] ≤11</title>
        <time_frame>week 12 &amp; 24</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Disease Activity Index [CDAI] ≤10</title>
        <time_frame>week 12 &amp; 24</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DAS28</title>
        <time_frame>up to 48 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EULAR Response</title>
        <time_frame>up to 48 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACR Score Individual Components</title>
        <time_frame>up to 48 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DAS28 Score Individual Components</title>
        <time_frame>up to 48 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pharmacokinetics</title>
        <description>AUC, Cmax, Tmax at baseline, and at Week (W) 2/Visit (V) 4, W4/V5, W8/V7, W12/V8, W24/V10, W3/V122, W48 (end of Treatment [EoT]/ early termination ET), and at follow-up (post EoT/post ET).</description>
        <time_frame>up to 48 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Evaluation of Safety, Patient Reported Outcomes &amp; Blood Tests.</title>
        <time_frame>up to 48 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>through study completion, up to 1 year</time_frame>
      <desc>All adverse events have been matched in accordance with the dosing under which they occurred. This resulted in a higher number of subjects at risk, because some subjects received two dosages. Patients who responded at week 12 continued the same treatment for 12 weeks and non-responders at week 12 were escalated to the next higher dose level or re-randomized to active treatment (placebo patients). After 24 weeks, placebo patients were switched to active treatment during the Extension Phase.</desc>
      <group_list>
        <group group_id="E1">
          <title>25mg Dose Level 1 Tregalizumab</title>
          <description>Dose Level 1 Tregalizumab (25mg)</description>
        </group>
        <group group_id="E2">
          <title>100mg Dose Level 2 Tregalizumab</title>
          <description>Dose Level 2 Tregalizumab (100mg)</description>
        </group>
        <group group_id="E3">
          <title>200mg Dose Level 3 Tregalizumab</title>
          <description>Dose Level 3 Tregalizumab (200mg)</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo -</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Multiple Injuries</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Road Traffic Accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Frostbite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Flavivirus Test Positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Multiple Sclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Cerebral Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Generalised Tonic-Clonic Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lichen Planus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Shock Haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="117"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="105"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="117"/>
                <counts group_id="E3" events="10" subjects_affected="7" subjects_at_risk="122"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rheumatoid Arthritis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="105"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="117"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="122"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="117"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="122"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to the lack of efficacy the Extension Phase of the study was terminated early.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Xuefei Zhou Manager Strategy &amp; Development</name_or_title>
      <organization>Biotest AG</organization>
      <phone>+496103801 ext 1229</phone>
      <email>xuefei_zhou@biotest.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

